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Background: To improve the outcome of patients with T-cell acute lymphoblastic leukemia (T-ALL),
characterization of the biological features of T-ALL blast cells and the immune status of patients with T-ALL is
needed to identify specific therapeutic strategies.
Findings: Using a novel approach based on the combination of fine-tiling comparative genomic hybridization
(FT-CGH) and ligation-mediated PCR (LM-PCR), we molecularly identified a malignant γδ + T cell clone with a
Vδ5Dδ2Jδ1 rearrangement that was paired with a T cell receptor (TCR) VγI and comprised a Vγ1Vδ5 T cell clone in a
relapse T-ALL patient. This malignant Vδ5 T cell clone disappeared after chemotherapy, but the clone was detected
again when disease relapsed post allogeneic hematopoietic stem cell transplantation (allo-HSCT) at 100 weeks.
Using PCR and GeneScan analyses, the distribution and clonality of the TCR Vγ and Vδ subfamilies were examined
before and after allo-HSCT in the patient. A reactive T cell clone with a Vδ4Dδ3Jδ1 rearrangement was identified in
all samples taken at different time points (i.e., 4, 8, 68, 100 and 108 weeks after allo-HSCT). The expression of this
Vδ4+ T cell clone was higher in the patient during complete remission (CR) post allo-HSCT and at disease relapse.
Conclusions: This study established a sensitive methodology to detect T cell subclones, which may be used to
monitor minimal residual disease and immune reconstitution.
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T-cell acute lymphoblastic leukemia (T-ALL) comprises
25% of adult ALL cases, and its outcome is poorly
understood. Among patients with T-ALL, approximately
40% achieve long-term remission [1-3]. Allogeneic
hematopoietic stem cell transplantation (allo-HSCT)
remains one of the best options for curing T-ALL. How-
ever, many patients cannot find an HLA-matched donor;
therefore, haploidentical/mismatched HSCTs may be an
alternative treatment for T-ALL [4,5]. The high T-ALL
failure rate is mainly the result of an insufficient un-
derstanding of T-ALL biology, which hampers the* Correspondence: miyadu@hotmail.com; yangqiuli@hotmail.com
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reproduction in any medium, provided the oridentification of reliable prognostic factors that enable
appropriate therapy adjustment [1]. To improve T-ALL
outcome, characterization of the biological features of
T-ALL blast cells and the immune status of patients is
needed to design specific therapeutic strategies [6-10].
T-ALL is generally considered to be a clonal disorder
that arises from the expansion of committed lymphoid
precursors, and leukemic clones in different patients
vary due to the T cell receptor (TCR) gene rearrange-
ments that occur during T-cell differentiation [1,11].
Moreover, TCR rearrangements also provide different
recombination breakpoints that lead to the creation of
fusion genes [12]. TCR rearrangement analysis may be
used to determine T-ALL immunogenetic characteristics,
and TCR rearrangements may be characterized by
leukemia antigen-reactive T cell clones, which are thought
to be specific to anti-leukemic cytotoxic T cells [13,14].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical therapy details for the patient with relapse T-ALL




18.11-01.12.2009 CTX, VCR, ADM, DXM PR 11 / 3 - MTX + DXM
18.12-22.12.2009 MTX, Ara-c , DXM NR 37 / 3
25.01-30.01.2010 CTX, Ara-c, TPT NR 47 / 1 - Ara-c + DXM
05.03.2010 Allo-HSCT
(conditioning regimen: Flu, BU/CY)
CR 1 / 0 - MTX + DXM
13.04.2010 CsA, MP GVHD (Grade II) 0.5 / 0
13.05.2010 CsA, MP GVHD under
control
1.5 / 0 - MTX + DXM
12.08.2010-
07.01.2011
Radiotherapy CNSL cured 0 / 0 + (Ara-c + MTX + DXM) x 8 times
26.04-21.05.2012 VDS, NVT, L-ASPDXM Relapse, CR 3 / 0 - MTX + DXM (03.05 2012) Ara-c + DXM
(25.05.2012)
08.06-06.07.2012 VCR, NVT, L-ASP, DXM, CTX CR 1 / 0 -
Notes: ADM adramycin, Ara-c cytarabine, BM bone marrow, BU busulfan, CNSL central nervous system leukemia, CsA cyclosporin, CSF cerebrospinal fluid,
CTX cyclophosphamide, CR complete remission, CY cyclophosphamide, DXM dexamethasone, Flu fludarabine, L-ASP l-asparaginase, MP methylprednisolone,
MTX Methotrexate, NR minor remission, NVT mitoxantrone, PR partial remission, PB peripheral blood, TPT Topotecan, VCR vincristine, VDS Vindesine.
Table 2 Clinical details of the collected samples
No. Diagnosis Disease status
A Relapse Relapse
B Pre allo-HSCT NR
C 4 W post allo-HSCT CR
D 8 W post allo-HSCT CR
E 68 W post allo-HSCT CR
F 100 W Relapse
G 108 W MRD
Notes: allo-HSCT: CR complete remission,
MTD minimal residual disease, NR minor remission.
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http://www.molecular-cancer.com/content/12/1/73In this study, using a novel approach based on the com-
bination of fine-tiling comparative genomic hybridization
(FT-CGH) and ligation-mediated PCR (LM-PCR) [15],
which combines PCR and the GeneScan techniques
[16,17], we molecularly characterized the malignant and
reactive γδ + T cell clones in a patient with T-ALL before
and after relapse 100 weeks post allo-HSCT.
A 25-year-old male patient was diagnosed with relapse
T-ALL in November 2009. The diagnosis was based on
cytomorphology, immunohistochemistry and cytoimmu-
nological analyses. He underwent salvage chemotherapies
for the next 3 months. However, his response assessments
were partial remission (PR), minor remission (NR), and
NR. In March 2010, the patient received an HLA-identical
sibling peripheral blood (PB) HSCT after a conditioning
regimen in addition to cyclosporin (CsA) in combination
with a short course of mycophenolate mofetil (MMF) and
four doses of methotrexate (MTX) for graft versus host
disease (GVHD) prophylaxis as previously described [18].
Lumbar puncture and intrathecal chemotherapy were
performed as normal. Four weeks after transplantation,
the patient was stricken with fever, diarrhea, and a rash,
which is considered Grade II GVHD. Eight weeks after
transplantation, the GVHD was controlled with methyl-
prednisolone (MP) and CsA treatment. Central nervous
system leukemia (CNSL) was found 20 weeks post trans-
plantation, and intrathecal chemotherapy and radiothe-
rapy of the head were then applied. The patient achieved
complete remission (CR) in the bone marrow and was
consistently normal upon cerebrospinal fluid examination
at 40, 52, and 68 weeks after transplantation. However, re-
lapse was discovered 100 weeks after transplantation, and
he underwent chemotherapy over the next two monthsand achieved remission. The treatment process is summa-
rized in Table 1, and the details of the regimens used are
summarized in Additional file 1: Table S1. As of this
reporting, the patient remains in follow-up. Blood samples
were collected with informed consent when the patient
was diagnosed with relapse T-ALL before transplantation
and at 4, 8, 68, 100 and 108 weeks post transplantation
(Table 2 and Additional file 1: Table S2). PB was collected
in an EDTA-containing collection tube, and PB mono-
nuclear cells (PBMCs) were separated using the Ficoll-
Hypaque gradient centrifugation method. All procedures
were conducted in accordance with the guidelines of the
Medical Ethics committees of Guangdong General Hospital
according the guidelines of the health bureau of Guangdong
Province, China.
Malignant T-ALL clone
To characterize the cellular T-ALL features and the T cell
clonality at different time points before and after allo-
HSCT and at relapse post allo-HSCT, which may identify
Figure 1 One TCR δ clone was identified by FT-CGH, LM-PCR and sequencing in a T-ALL case, and a Vδ5Dδ2Jδ1 rearrangement was
confirmed. A: FT-CGH analysis results for the TCR αδ locus in chromosome 14 with arrows indicating the breakpoints. B: Comparison of the
GenBank sequences within the Vδ5, Dδ2, and Jδ1 segments. C: Sequence of the Vδ5Dδ2Jδ1 splice junction from a purified LM-PCR product. The
sequences within the ellipse indicate the CDR3 segment including the Dδ2 and N regions.
Figure 2 The distribution and clonality of the TCR Vγ and Vδ subfamily T cells in a patient with T-ALL at different time points before
and after allo-HSCT. A: T-ALL relapse, B: pre-HSCT, C: 4 weeks post allo-HSCT, D: 8 weeks post allo-HSCT, E: 68 weeks post allo-HSCT,
F: 100 weeks post allo-HSCT and disease relapse, and G: 108 weeks post allo-HSCT and after one cycle of chemotherapy. The monoclonal Vδ5
subfamily could be found in samples A, F, and G, and the oligoclonal Vδ4 subfamily could be identified in samples C through G.
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breakpoint loci to identify chromosomal translocations
and malignant T cell clones by the FT-CGH, LM-PCR,
RT-PCT and GeneScan techniques [15-17].
FT-CGH using overlapping oligonucleotides designed
to cover an entire genomic region of interest is a va-
luable tool for high-resolution chromosomal breakpoint
characterization [15]. To achieve high resolution CGH
(<1 kb), which is necessary for subsequent in vitro DNA
amplification, a custom designed high-density, fine-tiling
long oligonucleotide array consisting of 385,000 oligonu-
cleotides 40–60 bp in length was prepared using MasklessFigure 3 The clonality and size of Vδ5 T cells in a patient with T-ALL
different time points including the following: A: relapse before allo-HSCT (t
post allo-HSCT, D: 8 weeks post allo-HSCT, E: 68 weeks post allo-HSCT (the
the malignant T cell clone with 466 bp), F: 100 weeks post allo-HSCT and d
and G: 108 weeks post allo-HSCT and after one chemotherapy cycle with m
product is still detectable). H: The expression level of the monoclonal the V
at 100 and 108 weeks post allo-HSCT and after one chemotherapy cycle wArray Synthesizer (MAS) technology (NimbleGen Systems;
Reykjavik, Iceland). This array, covering 24 Mb of genome,
was selected using the human genome browser hg18
assembly (University of California, Santa Cruz). The array
included TCR αδ and IgH loci, which are located on
chromosome 14q11 (Chr14: 21,130 -22,130 kb) and 14q32
(Chr14: 105,080 -106,360 kb), respectively, and known to
be frequently involved in chromosomal alterations in
lymphoid malignancies. The neighboring oligonucleotides
with an average distance of 63 bp were grouped in 200,
400, and 1,000 bp clusters. After normalization with refe-
rence DNA from the HEK293 T cell line, the meanat different time points. Vδ5 T cell clonality was measured at
he monoclonal Vδ5 product size was 466 bp), B: pre-HSCT, C: 4 weeks
clonal Vδ5 products were 459 and 477 bp, there were different from
isease relapse (a 466 bp monoclonal Vδ5 product is again observed),
inimal residual disease (MRD) remaining (a 466 bp monoclonal Vδ5
δ5 gene at different time points (i.e., relapse before allo-HSCT, relapse
ith MRD remaining).
Figure 4 The CDR3 sequence in the Vδ4Dδ3Jδ1 rearrangement. A: Sequence comparison of the Vδ4, Dδ3, and Jδ1 segments from GenBank;
B: sequence of the Vδ4Dδ3Jδ1 splice junction.
Figure 5 The Vδ4 gene expression level at different time points
post allo-HSCT.
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(NimbleGen) [15].
FT-CGH analysis of the TCR αδ locus (Chr 14: 21,130-
22,130) from the T-ALL sample revealed breakpoints at
the 21,700 kb (TCR Vδ5) and 22,000 kb (TCR Jδ1) loci
(Figure 1A). LM-PCR using nested forward primers spe-
cific to the TCR Vδ5 locus revealed a normal rear-
rangement i.e., a TCR Vδ5 to Jδ1 rearrangement. Direct
sequencing of these LM-PCR products demonstrated the
following details of the Vδ5Dδ2Jδ1 rearrangement: the Vδ5
breakpoint is located in chromosome 14 at position
21,701,606 and the Jδ1 breakpoint is located in chromo-
some 14 at position 21,988,926 (Figures 1B and C). To
confirm this TCR rearrangement, we used PCR to detect
the Vδ5 and Jδ1 loci with specific primers and undigested
genomic DNA. Thus, two 14q11.2 (TCR αδ) chromosome
breakpoints were characterized as a TCR idiotype re-
arrangement. Therefore, it may be concluded that there
were no additional breakpoints providing a recombination
point for the TCR αδ locus-related chromosomal trans-
location because the translocation of proto-oncogenes to
TCR loci most likely occurred as the cell attempted to
undergo V(D)J recombination, and it is likely that these
translocations arise as a mistake in this process, depending
on the location of the breakpoint in the receptor locus
[12,15,19,20]. Using RT-PCR, GeneScan, and sequencing
analysis, the Vδ5Dδ2Jδ1 rearrangement was confirmed to
be monoclonal (The information of the primers used for
TCR Vδ5-PCR was listed in Additional file 1: Table S3).
Monoclonally expanded Vδ5 T cells, which were
presumed to pair with the TCR VγI, comprised a VγIVδ5
T cell clone (Figure 2A). Significantly, this malignant
monoclone was lost after chemotherapy and allo-HSCT,
but there was a gain in polyclonal Vδ5 T cells, which may
pair with VγII T cells and comprise many normal VγIIVδ5
T cell clones (Figure 2B) that arise from normal random V(D)J rearrangements [1]. Although the GeneScan results
revealed biclonal Vδ5 T cells in the allo-HSCT sample
taken after 68 weeks, these T cell clones were different
from the malignant clone (Figure 3). The malignant
monoclonal Vδ5 product was 466 bp (Figure 3A), while
both of the clonal Vδ5 products from the post transplan-
tation sample were 459 and 477 bp (Figure 3E). Moreover,
the malignant monoclonal Vδ5 clone reemerged 100 weeks
after allo-HSCT treatment (Figure 3F), a time at which
the patient underwent relapse, and the Vδ5 subfamily also
included an oligoclone 108 weeks after allo-HSCT
(Figure 3G), which was after chemotherapy and when
the patient achieved remission. The CDR3 sequence of
the Vδ5 clones at diagnosis and 100 and 108 weeks post
allo-HSCT were determined, and the polyclonal and
biclonal Vδ5 T cell clones were found to contain different
CDR3 sequences with different sizes. The Vδ subfamily
members preferentially expressed in PB from healthy and
T-ALL clones include Vδ1 and Vδ2, while the Vδ5 clone
was reported to be rare [21,22]. Thus, this malignant T cell
clone may serve as a biomarker for the detection of
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containing the same sequence was found at disease relapse
100 weeks post allo-HSCT. Using quantitative real-time
PCR [23,24], we found that the expression level of the
malignant Vδ5+ T cell clone was high at diagnosis and
low when disease relapse was detected. In addition, the
Vδ5 expression level declined even further after chemo-
therapy at 108 weeks when the disease achieved remission
with minimal residual disease (i.e., 4% blast cells in the
bone marrow) (Figure 3). These data further indicate the
significance of dynamically monitoring malignant T cell
clones to molecularly identify relapse, which may provide
evidence for commencing treatments such as preventive
anti-leukemia therapy to clinically inhibit disease relapse.
The identification of malignant T-ALL cell clones was
performed at different times using Southern blot, PCR,
RT-PCR, GeneScan, FT-CGH, and next generation se-
quencing spectratyping [25]. The distribution profiles
and clonality of the TCR repertoire in T cells could be
characterized using RT-PCR and GeneScan [17]. While
an advantage of the FT-CGH and LM-PCR techniques is
that they can identify chromosomal breakpoints and
unique, high percentage T cell clones in a sample, they
cannot characterize the polyclonal TCR subfamily dis-
tribution or a small fraction of T cell clones [12]. The
novel, exhaustive T cell repertoire sequencing technique
can directly measure the TCR repertoire size of at least
1 million clonotypes [25]. Therefore, the combination of
the FT-CGH, LM-PCR, PCR, and GeneScan techniques
for characterizing T cell malignancies is an ideal serial
method not only for identifying abnormal chromosome
rearrangements in malignant T cell clones but also for
detecting the evolution of malignant T cell clones for the
diagnosis, prognosis, and evaluation of reactive T cell
clones to characterize the immune status of patients and
develop specific immunotherapies.
Clonally expanded reactive T cell clone
Numerous studies have demonstrated that specific
clonally expanded T cells may be identified in the PB of
patients with cancer and leukemia, demonstrating their
specific anti-leukemic cytotoxicity in vitro [13,26-28].
Moreover, clonally expanded T cells may be derived from
donor lymphocytes after allo-HSCT or donor lymphocyte
infusion (DLI), which may increase survival following allo-
HSCT in patients with advanced-stage acute leukemia
[26,29]. These clonally expanded T cells are derived from
TCR αβ or γδ T cells [10]. Increasing data have demon-
strated that γδ T cells may be used to develop specific im-
munotherapies for patients with cancers such as bladder
cancer and hepatocellular carcinoma [30]. After trans-
plantation, the patient achieved CR, and the distribution
and clonality of the TCR Vγ and Vδ subfamilies were
examined. While a malignant Vδ5+ T cell clone was notdetected, oligoclonally expanded Vδ4 subfamily T cells
were identified in samples from all time points (i.e., 4, 8,
68, 100, and 108 weeks post allo-HSCT) even after the
patient underwent relapse (100 weeks post allo-HSCT;
Figures 2C to G). The TCR sequence of the Vδ4+ T cell
clone was identified as Vδ4Dδ3Jδ1 by direct sequencing,
and the same TCR rearrangement was confirmed in all
samples from each of the time points post transplantation
(Figure 4). The Vδ4+ T cell clone increased more than
three-fold when the patient reached CR status post allo-
HSCT. Interestingly, the Vδ4 expression level gradually
increased 100 and 108 weeks post allo-HSCT, which was
when disease relapse occurred and after chemotherapy
was given, respectively (Figure 5). This observation sug-
gests that the increased Vδ4+ T cell clone may be a reac-
tively expanded T cell clone that has specific anti-T-ALL
function. Although the patient underwent GVHD 8 weeks
post transplantation, which was subsequently controlled,
the continuously expanded T cell clone may be not related
to GVHD. The higher proportion of Vδ4+ T cell clones in
samples taken after disease relapse may further support
the idea of its role as a reactively expanded anti-leukemia
T-cell clone. These results are similar to findings by
Meeh et al. who demonstrated that Vδ1+ T cells respond
to acute leukemia [28]. However, further characterization
of the biological functions of the Vδ4+ T cell clone is
needed; the reactive T cell clone may be amplified and
used to study adoptive anti-leukemia immunotherapy,
moreover, the TCR Vδ4 and its pattner Vγ gene could be
used for transfer and the modification of normal T cells
for identification their anti-leukemia effect [6,14,31,32].
In summary, the evolution of malignant TCR γδ+ and re-
active T cell clones was identified in a patient with relapse
T-ALL before and after allo-HSCT and at relapse post allo-
HSCT. The techniques used in this study establish the sensi-
tive detection of malignant and reactive T cell clones, and the
identified T cell clones may serve not only as biomarkers for
minimal residual disease detection but also as anti-leukemia
immune status indicators in patients who achieved CR.
Additional file
Additional file 1: Table S1. Details of Clinical therapy for the patient
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List of primers used for the Vδ5 TCR PCR.
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